February 14, 2018 / 7:31 AM / in 4 months

BRIEF-Pharma Mar Licenses Marine-Derived Payloads To Seattle Genetics

Feb 14 (Reuters) - PHARMA MAR SA:

* LICENSES FULLY SYNTHETIC MARINE-DERIVED PAYLOADS TO SEATTLE GENETICS FOR USE IN DRUG CONJUGATES

* SAYS WILL RECEIVE UPFRONT PAYMENT OF $5.0 MILLION ON SIGNING, FOLLOWED BY DEVELOPMENT MILESTONES IF A PRODUCT ENTERS CLINICAL DEVELOPMENT CONDUCTED BY SEATTLE GENETICS

* IS ELIGIBLE FOR POTENTIAL APPROVAL AND SALES MILESTONES, ROYALTIES, ONCE PRODUCT GETS REGULATORY APPROVAL AND IS COMMERCIALIZED Source text for Eikon:

Further company coverage: (Gdynia Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below